6:14 PM
 | 
Dec 05, 2012
 |  BC Extra  |  Company News

FDA reviewers: Zohydro likely to have 'higher levels of abuse'

FDA reviewers said they expect Zohydro ER hydrocodone bitartrate from Zogenix Inc. (NASDAQ:ZGNX) "will be associated with higher levels of abuse" than hydrocodone combination products. The comments came in briefing documents released ahead of a Friday meeting of the agency's Anesthetic and Analgesic Drug Products Advisory Committee to discuss an NDA for...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >